Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

28.89 -0.99 (-3.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about UroGen Pharma Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge ↗
This biotech firm develops therapies for urothelial cancers, leveraging proprietary delivery technology and a growing clinical pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally ↗
Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation. 
Via The Motley Fool
News headline image
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
From UroGen Pharma Ltd.
Via GlobeNewswire
UroGen Pharma (NASDAQ:URGN) Crushes Q1 Estimates as ZUSDURI Momentum Accelerates ↗
Via Chartmill
UROGEN PHARMA LTD (NASDAQ:URGN) Reports Mixed Q4 2025 Results Amid Strong Commercial Progress ↗
Via Chartmill
News headline image
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen (URGN) Q1 2026 Earnings Transcript ↗
UroGen (URGN) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
UroGen Pharma to Present at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026
Conference Call and Webcast Scheduled for Wednesday, May 6th, 2026, at 10:00 AM ET 
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? ↗
This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates. 
Via The Motley Fool
News headline image
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain ↗
Axsome Therapeutics develops therapies for central nervous system disorders, with a late-stage pipeline targeting major unmet medical needs. 
Via The Motley Fool
News headline image
Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet? ↗
This clinical-stage biotech develops therapies targeting the root cause of cystic fibrosis, with a pipeline focused on CFTR modulators. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names ↗
This clinical-stage biopharma targets neurological and psychiatric disorders with a pipeline of novel therapeutics advancing through trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Fund Sold $8 Million of Terns Stock Last Quarter, but Here's Why It Still Seems Very Bullish ↗
This clinical-stage biotech develops therapies for CML, NASH, and obesity. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen (URGN) Q4 2025 Earnings Call Transcript ↗
UroGen (URGN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026
Conference Call and Webcast Scheduled for Monday, March 2, 2026 at 10:00 AM ET 
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally ↗
A full exit after a monster rally says less about the company’s science and more about how disciplined funds lock in wins when portfolio math starts to matter. 
Via The Motley Fool
Topics Death Regulatory Compliance
News headline image
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen (URGN) Q3 2025 Earnings Call Transcript ↗
UroGen (URGN) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.